$XX.X for with joining versus million Glaukos quarter net thank and reported ago of year quarter. the us. sales first strong the start year Good to afternoon, Today, up everybody, you a XX%
to call. net also outlook Joe reaffirming XXXX the We’re discuss will our in million financial and later sales range our more in detail of $XXX million. $XXX guidance results
to aspirational of worldwide. mission towards therapy make continue We transforming progress our glaucoma
sustained optimized both portfolio solution capable devices are standalone at combo from and and each micro-invasive treatment surgical providing glaucoma disease severity, an therapies stage of cataract pharmaceutical severe the most to manifestation Our in and of of procedures. state the earliest
this two-stent combo eye of our context, being In over addition of enter by U.S. to ahead commence distinct American clinical and the which force XXX of Refractive Glaukos XXX to and to are the randomized and Subjects iStent our remained allows inject It to launch current to product launch U.S. iStent FDA ophthalmic achieve goal Three, our the combination XX module in was the presented update Recall multi-center XX inject in to progress continued inventories, were sales penetration trabecular of are our launch recently and by stents iStent surgeon at cataract subjects iStent for pharmaceutical and were moving this medication in campaign begin multiple click-and-release meshwork which to preparing were commercial subjects iStent XXXX. finalizing me investigational the randomized and sites actions FDA Samuelson, include the the Dr. annual patient locations enrollment and Consultants. only. iStent obtain let with Eye our with iStent submit glaucoma end activities. our subjects at our latter Surgery We clinical motion. Two, to also the drive of a made achieved of studies. four approval injectors are training on cataract five prospective with that Cataract capabilities XXX through this in international investment. for five to followed surgery XXXX. open-angle Minnesota scaling an Tom previously, a with increased injectors or that an to manufacturing we and pivotal U.S. markets, commercial announced inject surge key PMA advancing – device, final expand four, year one, These building later implement for preparations months the into products the were the in necessary to to study, surgeon launch marketing a Society facile the year Beginning inject in inject. Tom once In commercialization the and included key cataract through XXXX ASCRS randomized approval of targeted objectives to is part provide next In cascade years. surgery washouts. hopeful pipeline meeting trial
change. unmedicated therefore Particularly, cohort secondary percentage profile. inject as iStent We safety to pleased runway a at the show despite months an lower data met pre-operative showing inject with IOP XX.X of XX% overall pivotal mean arm efficacy XX XX% of comparable are millimeters mean baseline our the of favorable iStent endpoints delighted efficacy mercury. a from X.X an inject millimeters achieved the greater XX analysis the arm of or of unmedicated reduction observed unmedicated the of primary and in treatment mean and to XX% that its IOP with than baseline IOP mercury a mgs A study’s having IOP, we’re XX.X primary mercury less treatment in or the endpoint months millimeters iStent achieved roughly that trials lower reduction
are studies. our this is lower IOP reported other the to to measure While major inject believe comparable final we or than all comparisons difficult, iStent across from efficacy pivotal
the number reduction XX reduction XX% mean a medications group. inject In showed the control addition, a observed versus representing achieved iStent XX% cohort months that in data of a greater the
exceptional. inject combination the cataract with XX be appears was iStent cohort the only cohort. the surgery months, surgery cataract to the similar adverse for of inject rate Through Finally, in safety iStent to overall of events profile
nine now numerous presented, have reviewed surgeons this inject seasoned We that world are those studies meeting on to recent month's to real where performance iStent been obtained and publications We peer pivotal confident the evaluated presented have clinical clinical that trend. inject in iStent results inject clinical product. iStent this that testified Two at outperform achieving last combined are procedures appear studies in ASCRS studies. and of cataract
XX burden in three of at Fritz implantation. millimeters a and to eyes showing of Dr. Germany case a study XX.X in First with of mean to post with implanted series cataract XX% of combination reduction mercury years a inject iStent IOP presented Hengerer med XX% reduction surgery,
achieved presented up glaucoma Secondly, mean XX.X year XXX implantation. Harasymowycz implanted case of iStent combination to cataract mild mercury a inject with Dr. series of millimeters eyes and surgery of burden post Paul XX% one that to with with a and reduction med IOP the severe in in
generation below while reducing colleagues more XX and This a mercury combination efficacious medications Ahmed IOP study earlier iStent Ike iStent implants study implants. this may AGS Dr. versus of burden that millimeters reducing in further at X iStent the X surgery Finally, or inject inject presented with series of achieved medication in year at subjects year. concluded be cataract one case with showing
profound XX,XXX rate elegance iStent appetite glaucoma results surgical been performance, treatment a markets ophthalmic interest surveys the inject reliably who safety industry of be implanted in clinical option cataract manage awareness, U.S. will where facility we their in over injects implant and the iStent demonstrating international products the of and adoption procedure, patients. the compelling and efficacy believe Given for have the stellar rapid its surgeons predictable comorbid
enviable and product product our cascade next five Beyond a iStent of can for facilitate an a inject over growing surgical increase U.S. pipeline company market. expanding glaucoma more opportunity this build to commercialization years. current a believe delivering penetrate pharmaceutical that us to U.S. hybrid more products portfolio into addressable Glaukos and fulsomely targeted novel evolution this We in potentially continues allowing while global advances the our market in seven-fold deeply
the this make beginning the to continue quarter of development progress plan XXXX during with iDose first Travoprost. We on
enrollment non-compliance and our ubiquitous drug Preparations topical III Travoprost expect problem similar enroll approximately delivery to of subjects ocular, randomized on open we’ll II, hypertensive angle patient clinical or meet initial prospective mid-XXXX. patient we begin Phase but This Our X,XXX glaucoma will at sites. aimed Phase goal to international be trial the double-blind addressing iDose pivotal at platform and remain trial medications. by product schedule the to U.S. with iDose for
through ASCRS are and Berdahl the regulatory XX eluding millimeters term mercury, Annual seek iDose the as average from to II approvals millimeters for longer these the community an to John Meeting, iDose that XX-week Recall ILP efforts clinical the for recent the progressing interim of eluding Our At in cohort XX Dr. filed achieved and in iDose X.X first and showed versions very feedback compared that positive. of markets timolol. subjects results planned. respectively and X.X baseline and fast topical results study to for Phase European of time X.X the millimeters Travoprost presented was Travoprost also reductions of slow months, Japan
addressing a therapies more the ocular of will data recent intraocular to-date glaucoma believe also timolol delivery way reported pave with or therapies a no other iDose instrumental use rate of powerful ultimately but produce we algorithm low not we believe either more new the If Phase iDose a groups. adverse drug our and underscores profile effectively available elution other manage favorable pressure. hyperemia data FDA most in approved, required for to the generations for challenges patients iDose of patient patients’ to In treatment group II glaucoma This sustained on future and the of showed the iDose be control medications with in Travoprost topical addition, more events What's alone far Travoprost potential non-compliance XX% iDose surgeons also of in average platform readout events. diseases. compared adverse group the medications, in to safety combination thus overall where the only with
on refractory for our report the important first recently previous iStent trial milestone the I'm pipeline glaucoma our at for an three-stent our recent next Similar we multi-center to timing addition the expectations. severe a that This efficacy the the SA, iStent of a trial surgical IDE primary patient iStent line SLT endpoint will most products, procedure have in randomized SA Moving standalone non-inferiority achieving year patients. to to pleased with one in enrolled the is generation pivotal to pipeline, infinite, to post-operative.
three The application Katz, reveal continue discussions of design that protocols all a we a Lewis who Richard Following stents. IDE from for reductions of XX% baseline the to ASCRS, stents our subjects versus show around reductions than FDA pre-op the was response to prospective favorable potential achieved IOP. mean authored study stent trabecular continued single-arm at multi-center incremental At iStent infinite Dr. approach. with the born dose which or concept of unmedicated XX% study receive latest findings and clinical presented for bypass three at Glaukos-sponsored out IOP, post-operatively IOP of trial. to for three by the of Dr. of beginning performance at productive XX% reduction study achieved X.X the the greater FDA durability the without patients our to the versus and medication and in the be equal XXXX, IOP unmedicated submission years with
Supra, two-year progresses the pivotal the in follow-up through trial early or Finally, XXXX. suprachoroidal iStent for shunt patient
patients. that our Supra million a of patent our given the alleging patients, end, ocular and most enhancement growth a pool retained the iDose leadership the cadence pipeline shareholders, Microstent our rely employees, inventions for treatment infringement treated lawsuit To X our opportunity over formidable opportunity a position core and XXX,XXX annually. To we've the meeting will and refractory who glaucoma comprehensive against to infinite, viable moderate to iStent, more leading inject, hypertension technologies. platforms our next said, portfolio several the that and the inventions unwavering available and line benefits option to procedures Ivantis, U.S. to commitment decade. this protect patent continue well or in others approved a expand infringes see our space proprietary context portfolio to and be benefit of MIGS over their We lawsuit needs iStent the litigation if into uniquely expectations, reflects diagnosed glaucoma the represent for believe iStent landscape, we on profile, us. to intellectual combined are progressive firm treated protect sevenfold the iStent the aspect roughly today we as the a iStent of portfolio believe that of put This filed pipeline significantly from believe to proprietary customers, million solid second An Hydrus robust capable and of combination algorithms entire with in using SA, ability is As We property. such the we next open-angle to building treatment risk a important we expand the and estimate of glaucoma therapy a continuum at which over can addressable from Glaukos a years glaucoma. disease in eyes, Travoprost our of market market global XX suprachoroidal stage
including the third key Momentum this as OUS in first is We the Germany, objective direct currently year-over-year Brazil, sales have XX% for that our quarter. were international year-over-year. sales U.S. established to continues fully international Our growth outside our in the in Japan markets of into evidenced markets. and growth direct to deeper XXXX. XXXX operations UK countries build quarter XX XX drive drove by international XXXX
is establish our focus teams, clinical to quality, OUS to surgeons train makes favorable experienced, working surgical grow and data on sales adoption. compelling and reimbursement, Our while building leverage awareness
fourth capabilities through objective investment. Our our pharmaceutical is continued key expand to
most pathways. exploring a extensive Our seasoned and leading over and team sustained of pharmaceutical prior actively whom pharmaceutical of scientists, remain at novel experience companies treatment have other chemists experts, XX options
Rady President where growth a of the In to respected medical business we ophthalmology, position announce Vice addition executive surgical a to highly can in variety and is has within of and Jane augment that Corporate device AMO, our most evaluate seasoned Senior of Johnson at recently organic products Johnson development senior device decades. Development. end, vision, and addition in-licensing in pleased To served Business recent for roles efforts she business business. technologies pharmaceutical and and pharmaceutical Strategy growth, Labs, coming who that led the we're the are leadership Abbott & ophthalmic our beginning to the Jane sustain as and
vision are Nick of To We and people pleased made announce of Vice in Affairs. lead Vice Affairs and who capability. implement her have also company. strategic some have Clinical and and March. Nick of recently Medical the privileged Tarantino, has to our Senior Global with new Quality help responsibilities join as advancing, commercialization, to in over the us Wells, in Senior President, President hiring served and retired late pipeline recent assist to Jeff significant taken to to our Regulatory fulsome investments distinction as team our Glaukos I'm for the Clinical we
in sterling has join contributions we're us have opportunity made Glaukos in the You over and Nick so to pipeline. as Glaukos leadership and global where have operations R&D. AMO, of he many accruing positive his Allergan one distinguished richest career him excited clinical to Head build deliver he many within earned responsibility XX to on an plus was helping for pipelines recently research wish integral the affairs we had positions comes and and and and his Regulatory retirement. Jeff. and all a Officer We're medical of service by year of longstanding to served grateful best development, the ophthalmology. after for Nick to span AcuFocus in him robust Glaukos reputation where to in and presented the Chief our medical and most ophthalmology Clinical years
to that, financial call over summary the I'll turn of first with results. quarter So Joe for the a
